EXEL
Exelixis, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Exelixis has 10 disclosed suppliers and 4 disclosed customers in SEC filings.
Exelixis, Inc.
69.03
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIn addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.
SentenceCollaboration services revenues were reduced by $22.8 million and $21.3 million for the years ended December 31, 2025 and 2024, respectively, to account for the 3% royalty we are required to pay Royalty Pharma on the net sales by Ipsen and Takeda of any product containing cabozantinib.
SentenceIn addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.
EXEL 10-Kaccession 0000939767-26-000021
SentenceWe are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge.
EXEL 10-Kaccession 0000939767-26-000021
SentenceIn addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.
EXEL 10-Kaccession 0000939767-26-000021
SentenceTo meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.
EXEL 10-Kaccession 0000939767-26-000021
SentenceThe CRADA reflects a commitment by NCI-CTEP to provide funding for the broad exploration of cabozantinib's potential in a wide variety of cancers, each representing a substantial unmet medical need.
EXEL 10-Kaccession 0000939767-26-000021
SentenceAs part of our strategy to access clinical- or near-clinical-stage assets, we executed an exclusive option and license agreement and clinical development collaboration with Sairopa to develop ADU-1805.
EXEL 10-Kaccession 0000939767-26-000021
SentenceTo meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.
EXEL 10-Kaccession 0000939767-26-000021
SentenceTo Ipsen, we granted the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted such rights in Japan.
SentenceMINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.
EXEL 10-Kaccession 0000939767-26-000021
SentenceWe entered into a supply agreement with Ipsen to supply finished and labeled drug product for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply.
EXEL 10-Kaccession 0000939767-26-000021
Linked news
Expected move
Inputsspot 69.39exp Feb 19ATM strike 70ATM straddle 12.35IV 40%